116 related articles for article (PubMed ID: 27602952)
1. The significance of c.690G>T polymorphism (rs34529039) and expression of the CEBPA gene in ovarian cancer outcome.
Konopka B; Szafron LM; Kwiatkowska E; Podgorska A; Zolocinska A; Pienkowska-Grela B; Dansonka-Mieszkowska A; Balcerak A; Lukasik M; Stachurska A; Timorek A; Spiewankiewicz B; El-Bahrawy M; Kupryjanczyk J
Oncotarget; 2016 Oct; 7(41):67412-67424. PubMed ID: 27602952
[TBL] [Abstract][Full Text] [Related]
2. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
4. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
[TBL] [Abstract][Full Text] [Related]
5. p19(INK4d) mRNA and protein expression as new prognostic factors in ovarian cancer patients.
Felisiak-Golabek A; Dansonka-Mieszkowska A; Rzepecka IK; Szafron L; Kwiatkowska E; Konopka B; Podgorska A; Rembiszewska A; Kupryjanczyk J
Cancer Biol Ther; 2013 Oct; 14(10):973-81. PubMed ID: 24022213
[TBL] [Abstract][Full Text] [Related]
6. Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
Dimitrova D; Ruscito I; Olek S; Richter R; Hellwag A; Türbachova I; Woopen H; Baron U; Braicu EI; Sehouli J
Tumour Biol; 2016 Sep; 37(9):12329-12337. PubMed ID: 27297669
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
8. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
[TBL] [Abstract][Full Text] [Related]
9. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
11. [CEBPA gene mutation analysis in acute myeloid leukemia].
Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
[TBL] [Abstract][Full Text] [Related]
12. eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation.
Zhang Y; Yu JJ; Tian Y; Li ZZ; Zhang CY; Zhang SF; Cao LQ; Zhang Y; Qian CY; Zhang W; Zhou HH; Yin JY; Liu ZQ
Oncotarget; 2015 Sep; 6(28):25441-51. PubMed ID: 26213845
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
Brieau B; Auzolle C; Pozet A; Tougeron D; Bouché O; Soibinet P; Coriat R; Prieux C; Lecomte T; Goujon G; Marthey L; Rougier P; Bonnetain F; Ducreux M; Taieb J; Zaanan A
Dig Liver Dis; 2016 Apr; 48(4):441-5. PubMed ID: 26775096
[TBL] [Abstract][Full Text] [Related]
14. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
15. Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer.
Fujiwaki R; Hata K; Nakayama K; Fukumoto M; Miyazaki K
J Clin Oncol; 2000 Dec; 18(23):3946-51. PubMed ID: 11099324
[TBL] [Abstract][Full Text] [Related]
16. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma.
Fan Y; Fan J; Huang L; Ye M; Huang Z; Wang Y; Li Q; Huang J
Int J Clin Exp Pathol; 2015; 8(4):4132-7. PubMed ID: 26097603
[TBL] [Abstract][Full Text] [Related]
18. Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer.
Dansonka-Mieszkowska A; Szafron LM; Moes-Sosnowska J; Kulinczak M; Balcerak A; Konopka B; Kulesza M; Budzilowska A; Lukasik M; Piekarska U; Rzepecka IK; Parada J; Zub R; Pienkowska-Grela B; Madry R; Siwicki JK; Kupryjanczyk J
Oncotarget; 2018 Apr; 9(25):17735-17755. PubMed ID: 29707144
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.
Kim HS; Kim MK; Chung HH; Kim JW; Park NH; Song YS; Kang SB
Gynecol Oncol; 2009 May; 113(2):264-9. PubMed ID: 19203783
[TBL] [Abstract][Full Text] [Related]
20. Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer.
Tsubamoto H; Sonoda T; Yamasaki M; Inoue K
Anticancer Res; 2014 May; 34(5):2481-7. PubMed ID: 24778064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
